Editas Medicine

Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology. The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2013
Size (employees)
89 (est)+19%
Editas Medicine was founded in 2013 and is headquartered in Cambridge, US

Key People at Editas Medicine

Deborah Palestrant

Deborah Palestrant

Senior Director, Business Development & Strategy
Keith Joung

Keith Joung

Co - Founder
Kevin Bitterman

Kevin Bitterman

Interim President

Editas Medicine Office Locations

Editas Medicine has an office in Cambridge
Cambridge, US (HQ)
300 Third Street, First Floor

Editas Medicine Data and Metrics

Editas Medicine Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(97.2 m)

EBIT (FY, 2016)

(97.2 m)

Market capitalization (26-May-2017)

636.2 m

Closing share price (26-May-2017)

16.3

Cash (31-Dec-2016)

185.3 m

EV

470.9 m
Editas Medicine's current market capitalization is $636.2 m.
Numbers are in $, USDFY, 2016

R&D expense

57 m

General and administrative expense

46.3 m

Operating expense total

103.2 m

EBIT

(97.2 m)

Interest expense

62 k

Interest income

62 k

Net Income

(97.2 m)
Numbers are in $, USDFY, 2016

Cash

185.3 m

Accounts Receivable

88 k

Inventories

1.8 m

Current Assets

187.2 m

PP&E

40.4 m

Total Assets

229.2 m

Accounts Payable

4.6 m

Total Debt

20 m

Current Liabilities

33.1 m

Additional Paid-in Capital

320.1 m

Retained Earnings

(185.5 m)

Total Equity

134.6 m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.7 x
Numbers are in $, USDFY, 2016

Net Income

(97.2 m)

Accounts Receivable

88 k

Inventories

1.8 m

Accounts Payable

4.6 m
Y, 2016

EV/EBIT

-4.8 x

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.7 x

Editas Medicine Operating Metrics

FY, 2016

Patents Pending

500

Patents Issued

41

Editas Medicine Market Value History

Editas Medicine Online and Social Media Presence

Editas Medicine News and Updates

Editas Medicine Company Life and Culture

You may also be interested in